Kepler Capital analyst Christophe dombu maintained a Buy rating on MaaT Pharma (MAAT – Research Report) on March 12 and set a price target of ...
DelveInsight estimates approximately 52K cases of Graft Versus Host Disease in the 7MM. In 2023, the EU4 and the UK recorded ...
Hosted on MSN2mon
Maat Pharma Phase III microbiome trial hits endpoints as stock soarsFrench clinical-stage biotechnology and microbiome therapy company MaaT Pharma has seen success with its Phase III trial of MaaT013 meeting its primary endpoints, leading to a jump in the company ...
MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for MaaT013.
MaaT Pharma’s quest to bring a microbiota-based therapy to market has moved a step forward with new data showing a benefit for its MaaT013 candidate in an early-access programme (EAP).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results